Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2016

The Pharma Closeout tracks 57 deals, $511.5B in disclosed deal value, 52 with a post-close Outcome Score for the year 2016.

Median Critic Score: 75  ·  Median Outcome Score: 36

Best outcome: AbbVie Inc. / Boehringer Ingelheim GmbH (95)  ·  Weakest outcome: AbbVie Inc. / Stemcentrx, Inc. (9)

All 57 deals

• AbbVie Inc. / Boehringer Ingelheim GmbH — 2016 · $2.2B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Alere Inc. — 2016 · $5.8B · Worked — the deal delivered on its rationale.
• Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. — 2016 · $17.6B · Worked — the deal delivered on its rationale.
• Shire plc / Dyax Corp. — 2016 · $5.9B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Medivation Inc. — 2016 · $14.0B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Moderna, Inc. — 2016 · $250M · Worked — the deal delivered on its rationale.
• Sanofi S.A. / Boehringer Ingelheim GmbH (consumer healthcare business swap) — 2016 · $25.1B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / St. Jude Medical — 2016 · $30.5B · Worked — the deal delivered on its rationale.
• Astellas Pharma Inc. / Ganymed Pharmaceuticals — 2016 · $1.4B · Worked — the deal delivered on its rationale.
• LEO Pharma A/S / AstraZeneca plc — 2016 · $1.1B · Worked — the deal delivered on its rationale.
• Ipsen S.A. / Exelixis Inc. — 2016 · $855M · Worked — the deal delivered on its rationale.
• Shire plc / Baxalta Inc. — 2016 · $32.0B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / St. Jude Medical — 2016 · $25.0B · Worked — the deal delivered on its rationale.
• Jazz Pharmaceuticals PLC / Celator Pharmaceuticals — 2016 · $1.5B · Largely worked — most objectives met.
• AstraZeneca plc / Aspen Global Inc. (Aspen Pharmacare) — 2016 · $770M · Largely worked — most objectives met.
• Novo Holdings A/S / Catalent, Inc. — 2016 · $16.5B · Largely worked — most objectives met.
• Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) — 2016 · $4.3B · Largely worked — most objectives met.
• Mylan N.V. / Meda AB — 2016 · $9.9B · Mixed — partial payoff, real shortfalls.
• ICU Medical, Inc. / Pfizer Inc. (Hospira Infusion Systems business) — 2016 · $1.0B · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Synlogic — 2016 · $18M · Mixed — partial payoff, real shortfalls.
• Horizon Pharma plc / Raptor Pharmaceutical Corp. — 2016 · $860M · Mixed — partial payoff, real shortfalls.
• Lonza Group AG / Capsugel S.A. — 2016 · $5.5B · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / Anacor Pharmaceuticals — 2016 · $5.2B · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) — 2016 · $1.0B · Underwhelmed — fell short of the thesis.
• Lonza Group AG / Capsugel S.A. (KKR portfolio) — 2016 · $5.5B · Underwhelmed — fell short of the thesis.
• Novartis AG / Selexys Pharmaceuticals Corporation — 2016 · $665M · Underwhelmed — fell short of the thesis.
• AstraZeneca plc / Pfizer Inc. — 2016 · $1.6B · Underwhelmed — fell short of the thesis.
• Bayer AG / Monsanto Company — 2016 · $63.0B · Underwhelmed — fell short of the thesis.
• Celgene Corporation / Jounce Therapeutics Inc. — 2016 · $2.7B · Did not work — the deal failed to deliver.
• Sumitomo Dainippon Pharma Co., Ltd. (Sunovion Pharmaceuticals Inc.) / Cynapsus Therapeutics Inc. — 2016 · $624M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Padlock Therapeutics, Inc. — 2016 · $600M · Did not work — the deal failed to deliver.
• Novartis AG / Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc. — 2016 · $1.4B · Did not work — the deal failed to deliver.
• AbbVie Inc. / argenx SE — 2016 · $685M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cormorant Pharmaceuticals AB — 2016 · $520M · Did not work — the deal failed to deliver.
• Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc. — 2016 · $780M · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Actavis Generics business) — 2016 · $40.5B · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / IOmet Pharma Ltd. — 2016 · $400M · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / Afferent Pharmaceuticals, Inc. — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Anda Inc.) — 2016 · $500M · Did not work — the deal failed to deliver.
• F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc. — 2016 · $535M · Did not work — the deal failed to deliver.
• Allergan plc / Anterios, Inc. — 2016 · $90M · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. / Galapagos NV — 2016 · $2.1B · Did not work — the deal failed to deliver.
• Allergan plc / Topokine Therapeutics, Inc. — 2016 · $85M · Did not work — the deal failed to deliver.
• Allergan plc / Tobira Therapeutics, Inc. — 2016 · $1.7B · Did not work — the deal failed to deliver.
• Allergan plc / ForSight VISION5, Inc. — 2016 · $95M · Did not work — the deal failed to deliver.
• Adaptimmune Therapeutics plc / GlaxoSmithKline plc — 2016 · $500M · Did not work — the deal failed to deliver.
• Allergan plc / Vitae Pharmaceuticals, Inc. — 2016 · $639M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Bamboo Therapeutics, Inc. — 2016 · $645M · Did not work — the deal failed to deliver.
• Allergan plc / Heptares Therapeutics Ltd. — 2016 · $790M · Did not work — the deal failed to deliver.
• Novartis AG / Ziarco Group Limited — 2016 · $420M · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx, Inc. — 2016 · $9.8B · Did not work — the deal failed to deliver.
• Pfizer Inc. / Allergan plc — 2016 · $160.0B
• Genentech, Inc. (F. Hoffmann-La Roche AG) / Hanmi Pharmaceutical Co. Ltd. — 2016 · $910M
• Hanmi Pharmaceutical Co. Ltd. / Boehringer Ingelheim GmbH — 2016 · $730M
• Janssen Biotech, Inc. (Johnson & Johnson) / MacroGenics, Inc. — 2016 · $740M
• AstraZeneca plc / Allergan plc — 2016 · $1.5B

← Deal Library  ·  Interactive search  ·  How we score deals